Once-weekly 7.2 mg semaglutide dose delivers greater weight loss and health benefits in obesity: global study

An international research collaboration led by investigators from Canada, the US, Denmark, Norway, and Portugal has demonstrated that a higher weekly dose of semaglutide—7.2 mg—produces significantly greater weight loss and metabolic improvements in adults with obesity than the currently approved 2.4 mg dose. Published Monday in The Lancet Diabetes & Endocrinology, the study’s findings provide promising evidence that this higher dose is safe, effective, and could offer a new therapeutic option for individuals with obesity, including those living with type 2 diabetes (T2D).

Key findings from the phase 3 STEP UP and STEP UP T2D clinical trials, which spanned 72 weeks, showed:

• Adults without diabetes on 7.2 mg lost an average of nearly 19% of their body weight, compared to 16% with 2.4 mg and 4% with placebo. Nearly half of the higher-dose group lost 20% or more, with about one-third losing at least 25%.

• Adults with obesity and type 2 diabetes also experienced significantly greater weight loss—13% average with 7.2 mg versus 10% with 2.4 mg and 3.9% with placebo—alongside reductions in blood sugar levels, waist circumference, and cholesterol.

• The higher dose was generally well tolerated. Mild gastrointestinal side effects such as nausea and diarrhea were the most common, typically resolving without serious complications or treatment dropouts. Importantly, no increase in severe hypoglycemia or major adverse events was reported.

Expert perspectives underpin the study’s significance. Professor Lora Heisler, Director of Research at the University of Aberdeen’s Rowett Institute, commented that the greater weight loss achieved with 7.2 mg semaglutide marks a positive step in expanding treatment options for obesity, which remains a major global public health challenge. However, she noted the importance of regulatory scrutiny to balance efficacy with safety, emphasizing that individual patient needs must guide treatment decisions.

Semaglutide mimics the hormone glucagon-like peptide-1 (GLP-1), which regulates insulin secretion and appetite, thus reducing food intake and improving metabolic control. It is already approved for weight management at doses up to 2.4 mg weekly. These new findings suggest that increasing the dose to 7.2 mg can further enhance its therapeutic benefits without compromising safety.

Contextually, obesity affects over 650 million adults worldwide and contributes substantially to cardiovascular disease, diabetes, and other chronic conditions. Traditional interventions such as diet and exercise often result in limited sustained weight loss. Pharmacological approaches like semaglutide thus represent an important addition to the management arsenal, especially for patients who struggle to achieve clinically meaningful weight reductions.

The study also highlights several important public health implications:

• With nearly half the participants on 7.2 mg achieving a 20% or more weight loss, this dose could increase the proportion of patients meeting guideline-recommended targets for obesity-related health improvements.

• Improvements in waist circumference, blood pressure, and cholesterol can reduce the risk of cardiovascular events and improve overall metabolic health.

• The tolerability profile supports broader use, although clinicians must counsel patients about common side effects and monitor for adverse events.

Limitations and considerations remain:

• Long-term safety beyond 72 weeks requires further research.

• Additional studies are needed to assess whether higher doses impact body composition differently, such as potential muscle loss.

• Cost and accessibility of higher-dose formulations may affect real-world adoption.

Practical implications for readers include understanding that semaglutide is a medication administered by weekly injection, used alongside lifestyle changes. Patients living with obesity or T2D interested in this treatment should discuss it with their healthcare provider, weighing the benefits and side effects in their individual context.

In summary, extending semaglutide dosing to 7.2 mg weekly achieves clinically relevant, greater weight loss and metabolic benefits with an acceptable safety profile. It represents a promising advance in obesity treatment, potentially enabling more people to reduce obesity-related health risks. Continued studies will clarify its long-term use and optimal patient selection.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References: